To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for adjuvant treatment of resected stage III and IV melanoma.
 
Status In progress
Process STA pre-2018
ID number 1316

Provisional Schedule

Expected publication 16 January 2019

Project Team

Project lead Thomas Feist

Email enquiries

Consultees

Companies sponsors Bristol-Myers Squibb
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Melanoma UK
Professional groups Association of Cancer Physicians
  British Association of Dermatologists
  British Association of Skin Cancer Specialist Nurses
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety - Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
16 October 2018 Committee meeting: 2
10 September 2018 - 28 September 2018 Appraisal consultation
16 August 2018 Committee meeting: 1
09 March 2018 Invitation to participate
05 January 2018 - 02 February 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
31 July 2017 In progress, DH referral received
09 March 2017 Invitation to partipate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance